BaoPharma

BaoPharma (Jiangsu) Co., Ltd. is a clinical-stage biopharmaceutical company based in Wuxi, China, specializing in the discovery and development of innovative antibody-based therapeutics. As the clinical development subsidiary of Biosion, Inc., BaoPharma advances a diverse pipeline targeting oncology and autoimmune diseases. The company utilizes proprietary platforms, such as the H3 antibody discovery engine, to produce high-affinity monoclonal and bispecific antibodies. Its lead candidate, BPB-101, is an anti-Claudin 18.2 monoclonal antibody currently undergoing Phase 1/2 clinical trials for gastric and pancreatic cancers. BaoPharma also manages the China-based clinical programs for other Biosion assets, including therapies targeting TSLP and CD40. Through strategic collaborations and internal R&D, the company aims to address significant unmet medical needs in the global healthcare market.